Immuno-oncology (IO), emerging as a novel approach to taking advantage of the body's immune system to fight cancer, has been a game changer in cancer treatment research. With abundant drug development experience over the past years, Creative Biolabs is dedicated to offering a full range of IO therapy development services, and recently has introduced upgraded GTOnco™ immuno-oncology assay services at the 10th Annual Immuno-Oncology Summit on October 12, 2022.
Creative Biolabs participates in this great event in the field of IO research as the corporate sponsor and exhibitor. The on-site scientists enjoyed the brilliant speeches, especially about new emerging technologies for IO targeting and discovery and overcoming resistance to IO therapy, and met many old and new friends on booth #9. The most asked service is the newly-updated immuno-oncology assay services, which cover:
- GTOnco™ I-O Assays for In Vitro Study
For gene therapy-based I-O drug discovery, Creative Biolabs has updated a variety of proof-of-concept in vitro assays to test the pharmacological activity with a groundbreaking platform for in vitro testing of I-O agents.
The platform will greatly facilitate immune system activation study by well-established and custom designed assays, specifically for the research on cytokine release and activation of various immune cells.
Immune cell-mediated anti-tumor effect study is another focus of Creative Biolabs’ scientist team, who is experienced in a variety of immune cell-mediated cancer cell killing strategies including NK or effector T cells. A range of in vitro assay services to study the regulation of the tumor microenvironment and immune cell-mediated anti-tumor immune response profiling are also available to support clients’ gene therapy-based I-O drug discovery.
- GTOnco™I-O Assays for In Vivo Study
This innovative platform also provides a comprehensive approach for in vivo efficacy studies and underlies the safety profile and action mechanisms of candidate I-O drugs, in the presence of a functionally immunocompetent system.
For in vivo cytokine response assay, Creative Biolabs provides various cytokine detection by ELISA or ELISpot assays, such as chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.
For lymphocyte activation and proliferation assays, Creative Biolabs is able to provide faster, easier-to-use methods for measuring T-cell activation and proliferation in response to a variety of stimuli.
GTOnco™ also covers unique needs of clients’ projects by offering T cell persistence & trafficking assay, immune cell-mediated tumor regression assay, TCR-pMHC dissociation kinetics, and redirected T cell cytotoxicity assay
On December 4-8, 2022, Creative Biolabs will participate in the Antibody Engineering & Therapeutics (US) in San Diego, CA, and look forward to meeting more friends at booth #418. Find more information about one-stop gene therapy development services and upcoming events at https://www.creative-biolabs.com/gene-therapy/.
About Creative Biolabs
With years of experience in providing one-stop preclinical development services, Creative Biolabs has built a team of experts with solid knowledge of gene therapy, and is fully competent in providing services for worldwide clients. The services include but are not limited to gene delivery system development, gene editing, RNAi therapy development, safety and toxicology analysis, potency tests, and solutions of specific gene therapy development for diseases.
